BioTime Reports Interim Results on Reneviaa Clinical Safety Trial

In his presentation, Dr. Tew will announce that enrollment in a safety trial evaluating Renevia a , a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, is complete.

http://eon.businesswire.com/news/eon/20131028005634/en/BioTime-Reports-Interim-Results-Renevia%E2%84%A2-Clinical-Safety